Starting September 22, 2025, the prices of several medicines and medical devices will come down as the government has decided to remove GST on products earlier under the 5% slab. This move, announced by the National Pharmaceutical Pricing Authority (NPPA) after the 56th GST Council meeting, is expected to directly benefit patients by reducing their out-of-pocket medical expenses.
What Has Changed?
Until now, medicines and devices in the 5% GST slab carried tax, but under the new directive, they will be completely exempt (0% GST). However, medicines that were taxed at 12% will remain unchanged.
This reform is part of the government’s ongoing effort to make essential healthcare more affordable and accessible.
NPPA’s Directive to Pharma Companies
The NPPA has issued strict instructions to all pharmaceutical manufacturers and marketing companies:
- Revise the Maximum Retail Price (MRP) of products from September 22, 2025.
- Share the revised or supplementary price list with dealers, retailers, state drug controllers, and government bodies.
- Ensure that the full benefit of the GST exemption reaches consumers and patients without delay.
The authority has clearly stated that companies cannot keep the tax benefit for themselves—it must reflect in the final product price.
Public Awareness Campaigns
To maintain transparency, NPPA has recommended companies to:
- Spread the word through print, electronic, and social media.
- Run advertisements in local languages and national newspapers.
- Inform dealers, retailers, and customers about the price reduction.
This communication push is aimed at ensuring people know about the new lower MRPs and do not overpay.
Also Read : First Cargo Train From Kashmir to Delhi Launched, Boosting Apple Transport
What About Existing Stock?
The NPPA has clarified that companies do not need to recall, relabel, or re-sticker stock already in the market before September 22. Instead, if they can ensure compliance at the retail level and inform consumers properly, the old stock can still be sold.
Industry Response
Industry leaders have welcomed the move. According to Rajiv Nath, Forum Coordinator of AiMeD, the decision strikes a balance between consumer interests and business ease, preventing wastage of packaging material while ensuring price transparency.
Pharma companies have also been given the option to re-label stock in a phased manner, if they wish, to avoid shortages of essential medicines and devices.
Wider GST Benefits for Healthcare
Earlier this month, the GST Council also announced:
- Complete GST removal (12% to 0%) on 33 life-saving drugs used for cancer and rare diseases.
- Tax exemption on three more vital medicines (from 5% to 0%).
- Reduction of GST on other medicines from 12% to 5%.
- Lower GST on medical devices such as surgical equipment, diagnostic kits, dental apparatus, bandages, and glucometers—from 12–18% down to just 5%.
Why This Matters
This is a major relief for patients and families, especially at a time when healthcare costs are rising. With the GST cut, the prices of life-saving drugs and common medical products will drop, ensuring better access and affordability across India.The government, through NPPA, is not only helping patients but also ensuring that the pharma industry follows fair practices in passing on the benefits.
